The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.

Veliparib: a new therapeutic option in ovarian cancer?

Ghisoni, Eleonora;Giannone, Gaia;Tuninetti, Valentina;Genta, Sofia;Scotto, Giulia;Aglietta, Massimo;Sangiolo, Dario;Valabrega, Giorgio
Last
2019

Abstract

The role of poly ADP ribose polymerase inhibitors in ovarian cancer is rapidly evolving. Three different poly ADP ribose polymerase inhibitors (olaparib, niraparib and rucaparib) have been already approved as maintenance after response to platinum-based chemotherapy; two of them (olaparib and rucaparib) also as single agents. Veliparib, a novel PARPI, showed promising results in preclinical and early clinical settings. The aim of this review is to discuss veliparib's mechanisms of action, to provide a clinical update on its safety and activity in ovarian cancer, and to highlight future perspectives for its optimal use. Veliparib favorable toxicity profile encourages its use either as monotherapy or in combination. Its peculiar neuroprotective and radio-sensitizing effect warrant further investigation.
May 10
10
1
12
BRCA mutations; BRCA-mutated ovarian cancer; maintenance treatment; ovarian cancer; poly (ADP-ribose) polymerase (PARP) inhibitors; veliparib
Ghisoni, Eleonora; Giannone, Gaia; Tuninetti, Valentina; Genta, Sofia; Scotto, Giulia; Aglietta, Massimo; Sangiolo, Dario; Mittica, Gloria; Valabrega, Giorgio
File in questo prodotto:
File Dimensione Formato  
fon-2018-0883.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 1.78 MB
Formato Adobe PDF
1.78 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1701974
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 7
social impact